| Patient | Ernest Hemingway |
|---|---|
| Date of birth | 1970-07-21 |
| Identifiers | MRN HR-ET003-SYN; SSN (made up) 000-03-7419 |
| Document date | 2026-11-01 |
| Author | Walter Brandt-Ochoa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care: heavy drinking, low mood and forgetfulness a year after two plane crashes, with high blood pressure and abnormal liver and iron tests on the intake panel. Concerns: He is afraid of losing his memory and his ability to write; He wants to drink less without being told he must never drink again; He worries about headaches and pain since the crashes. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking | One tablet daily | Oral route | 2026-03-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-08-31 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Sertraline 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-13 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-06-08 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-08 | active | S |
| Cephalexin 500 mg oral capsule, one capsule four times daily for seven days | One capsule four times daily for seven days | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Doxycycline hyclate 100 mg oral capsule, one capsule twice daily for seven days, with a full glass of water, sitting upright | One capsule twice daily for seven days | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for pain, no more than 2,000 mg a day while he is drinking | One or two tablets every 6 hours as needed, up to 2,000 mg a day | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram at the diagnosis of hypertension: sinus rhythm at 86, normal intervals, borderline voltage for left ventricular hypertrophy | 2026-03-02 to 2026-03-02 | completed | S |
| Transient elastography of the liver in the hepatology clinic: liver stiffness 9.4 kPa (indeterminate); controlled attenuation parameter 288 dB/m (fatty change) | 2026-03-16 to 2026-03-16 | completed | S |
| MRI of the liver without contrast with R2* liver iron quantification and magnetic resonance elastography: liver iron concentration about 9.8 mg Fe/g dry weight (raised); stiffness 3.1 kPa, in keeping with mild fibrosis and no advanced fibrosis or cirrhosis; no liver lesion | 2026-04-13 to 2026-04-13 | completed | S |
| Transthoracic echocardiogram for stage 2 hypertension and iron overload: mild concentric left ventricular hypertrophy, ejection fraction 60%, normal diastolic filling for age, no features of iron-related cardiomyopathy | 2026-08-31 to 2026-08-31 | completed | S |
| Therapeutic phlebotomy, 500 mL weekly at the clinic's infusion room, with a hemoglobin check before each session (held if under 12.0 g/dL); twenty-two sessions before the six-month visit | 2026-03-23 | in-progress | S |
| Advance care planning conversation, about 18 minutes | 2026-07-27 to 2026-07-27 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-05-11 | Tdap vaccine for a tetanus-prone wound; last tetanus booster more than ten years ago | completed | S |
| 2026-07-27 | Pneumococcal conjugate vaccine (PCV20), one dose for chronic liver disease and alcohol use disorder | completed | S |
| 2026-07-27 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-07-27 | Hepatitis A and hepatitis B vaccine, dose 1 of 3, for chronic liver disease after nonreactive hepatitis B tests | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1918 | Wounded by a mortar shell near Fossalta di Piave while serving with an ambulance unit in Italy, with a long hospital stay | D (CLM-0002) |
| January 1954 | Two plane crashes in Uganda on consecutive days: concussion and skull fracture, ruptured right kidney, and liver and spleen injuries, with lasting pain | D (CLM-0004) |
| by 1954 | Heavy drinking for most of his adult life | D (CLM-0003) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Depression and diabetes; died by suicide in 1928 | D (CLM-0007) |
| Concern | Status | Evidence |
|---|---|---|
| He is afraid of losing his memory and his ability to write | active | S |
| He wants to drink less without being told he must never drink again | active | S |
| He worries about headaches and pain since the crashes | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.4 on 2026-08-31; MCV [Entitic mean volume] in Red Blood Cells by Automated count 93 on 2026-08-31; Platelets [#/volume] in Blood by Automated count 226 on 2026-08-31; Sodium [Moles/volume] in Serum or Plasma 138 on 2026-03-02; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-03-02; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 2026-03-02; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 91 on 2026-03-02; Glucose [Mass/volume] in Serum or Plasma 96 on 2026-03-02; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 2026-08-31; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 2026-08-31; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 41 on 2026-08-31; Bilirubin.total [Mass/volume] in Serum or Plasma 1 on 2026-03-02; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-03-02; Iron [Mass/volume] in Serum or Plasma 148 on 2026-08-31; Iron saturation [Mass Fraction] in Serum or Plasma 44 on 2026-08-31; Ferritin [Mass/volume] in Serum or Plasma 268 on 2026-08-31; Hemoglobin A1c/Hemoglobin.total in Blood 5.9 on 2026-08-31; Cholesterol [Mass/volume] in Serum or Plasma 194 on 2026-08-31; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 114 on 2026-08-31; Cholesterol in HDL [Mass/volume] in Serum or Plasma 49 on 2026-08-31; Triglyceride [Mass/volume] in Serum or Plasma 136 on 2026-08-31; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-03-02; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 412 on 2026-03-02; Albumin/Creatinine [Mass Ratio] in Urine 14 on 2026-03-02; Total score [AUDIT] 26 on 2026-03-02; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-07-27; Total score [MoCA] 27 on 2026-08-31; Liver stiffness by US.transient elastography 9.4 on 2026-03-16; Total score [AUDIT-C] 0 on 2026-08-31 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe; heavy daily drinking for most of his adult life; synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of DSM-5-TR severe alcohol use disorder (seven criteria); person-first language; not a claim about his real diagnosis. |
| Raised transferrin saturation and ferritin found on routine intake tests, cause not yet known (heavy drinking, liver disease or iron overload) | resolved | confirmed | R79.0 | S — Synthetic presenting finding; superseded when HFE testing gave the diagnosis. |
| Hereditary hemochromatosis, HFE C282Y homozygous, with iron overload (ferritin over 1,000 ng/mL) and no advanced liver fibrosis on imaging | active | confirmed | E83.110 | S — Synthetic modern diagnosis. Whether he had hemochromatosis is disputed (CLM-0013); the modern diagnosis is not offered as proof of it. |
| Major depressive disorder, single episode, moderate; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about his real mood. The roster's bipolar disorder lead is disputed (CLM-0014) and is not used. |
| Essential hypertension, stage 2, with heavy drinking contributing | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed by home readings. |
| Post-concussion symptoms (headaches, slowed thinking and forgetfulness) after repeated head injuries, most recently a concussion with a skull fracture a year ago; chronic traumatic encephalopathy is not diagnosed | active | confirmed | F07.81 | S — Synthetic modern diagnosis anchored to his documented head injuries; alcohol and depression also affect the symptoms. |
| Prediabetes (HbA1c 6.1%) | active | confirmed | R73.03 | S — Synthetic finding on diabetes screening; iron overload and alcohol both raise the risk of diabetes. |
| Fishhook puncture wound of the right hand with early cellulitis after saltwater exposure, in a man with iron overload; treated with antibiotics covering Vibrio; resolved | resolved | confirmed | L03.113 | S — Synthetic acute illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-02 | Hemoglobin [Mass/volume] in Blood | 15.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-03-02 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 102 | fL | 80-100 fL | High | S |
| 2026-03-02 | Platelets [#/volume] in Blood by Automated count | 208 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-02 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 91 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-02 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 70 | U/L | 10-40 U/L | High | S |
| 2026-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 78 | U/L | 7-55 U/L | High | S |
| 2026-03-02 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 196 | U/L | 8-61 U/L | High | S |
| 2026-03-02 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-03-02 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-03-02 | Iron [Mass/volume] in Serum or Plasma | 214 | ug/dL | 65-175 ug/dL | High | S |
| 2026-03-02 | Iron saturation [Mass Fraction] in Serum or Plasma | 76 | % | 20-50% | High | S |
| 2026-03-02 | Ferritin [Mass/volume] in Serum or Plasma | 1460 | ng/mL | 24-336 ng/mL | High | S |
| 2026-03-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.1 | % | 4-5.6% | High | S |
| 2026-03-02 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-03-02 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 118 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-03-02 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-03-02 | Triglyceride [Mass/volume] in Serum or Plasma | 236 | mg/dL | <=149 mg/dL | High | S |
| 2026-03-02 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-03-02 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 412 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-03-02 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g | <=29 mg/g | Normal | S |
| 2026-03-02 | Total score [AUDIT] | 26 | {score} | S | ||
| 2026-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 16 | {score} | S | ||
| 2026-03-02 | Total score [MoCA] | 25 | {score} | S | ||
| 2026-03-16 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 10-40 U/L | High | S |
| 2026-03-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 66 | U/L | 7-55 U/L | High | S |
| 2026-03-16 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 160 | U/L | 8-61 U/L | High | S |
| 2026-03-16 | Ferritin [Mass/volume] in Serum or Plasma | 1395 | ng/mL | 24-336 ng/mL | High | S |
| 2026-03-16 | Liver stiffness by US.transient elastography | 9.4 | kPa | Below 7.0 kPa makes significant fibrosis unlikely; 12.5 kPa or more suggests cirrhosis | High | S |
| 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-04-13 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 99 | fL | 80-100 fL | Normal | S |
| 2026-04-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 10-40 U/L | High | S |
| 2026-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 7-55 U/L | Normal | S |
| 2026-04-13 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 104 | U/L | 8-61 U/L | High | S |
| 2026-04-13 | Ferritin [Mass/volume] in Serum or Plasma | 1180 | ng/mL | 24-336 ng/mL | High | S |
| 2026-04-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S | ||
| 2026-04-13 | Total score [AUDIT-C] | 7 | {score} | S | ||
| 2026-06-08 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-06-08 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 96 | fL | 80-100 fL | Normal | S |
| 2026-06-08 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 10-40 U/L | Normal | S |
| 2026-06-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 36 | U/L | 7-55 U/L | Normal | S |
| 2026-06-08 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 8-61 U/L | Normal | S |
| 2026-06-08 | Ferritin [Mass/volume] in Serum or Plasma | 620 | ng/mL | 24-336 ng/mL | High | S |
| 2026-06-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-06-08 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-08-31 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.5-17.5 g/dL | Low | S |
| 2026-08-31 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 93 | fL | 80-100 fL | Normal | S |
| 2026-08-31 | Platelets [#/volume] in Blood by Automated count | 226 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-31 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 10-40 U/L | Normal | S |
| 2026-08-31 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 2026-08-31 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 8-61 U/L | Normal | S |
| 2026-08-31 | Iron [Mass/volume] in Serum or Plasma | 148 | ug/dL | 65-175 ug/dL | Normal | S |
| 2026-08-31 | Iron saturation [Mass Fraction] in Serum or Plasma | 44 | % | 20-50% | Normal | S |
| 2026-08-31 | Ferritin [Mass/volume] in Serum or Plasma | 268 | ng/mL | 24-336 ng/mL | Normal | S |
| 2026-08-31 | Cholesterol [Mass/volume] in Serum or Plasma | 194 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-08-31 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 114 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-08-31 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 49 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-08-31 | Triglyceride [Mass/volume] in Serum or Plasma | 136 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-31 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | 4-5.6% | High | S |
| 2026-08-31 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-08-31 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-08-31 | Total score [MoCA] | 27 | {score} | S | ||
| 2026-07-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-02 | Body height | 183 | cm | S |
| 2026-03-02 | Body weight | 98 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 29.3 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 152 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 88 | /min | S |
| 2026-03-02 | Respiratory rate | 16 | /min | S |
| 2026-03-02 | Body temperature | 36.8 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-03-16 | Body height | 183 | cm | S |
| 2026-03-16 | Body weight | 97.4 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 29.1 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 144 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 84 | /min | S |
| 2026-03-16 | Respiratory rate | 16 | /min | S |
| 2026-03-16 | Body temperature | 36.7 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-04-13 | Body height | 183 | cm | S |
| 2026-04-13 | Body weight | 96.2 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 28.7 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 80 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 36.6 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-06-08 | Body height | 183 | cm | S |
| 2026-06-08 | Body weight | 94.6 | kg | S |
| 2026-06-08 | Body mass index (BMI) [Ratio] | 28.2 | kg/m2 | S |
| 2026-06-08 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-06-08 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-06-08 | Heart rate | 76 | /min | S |
| 2026-06-08 | Respiratory rate | 14 | /min | S |
| 2026-06-08 | Body temperature | 36.7 | Cel | S |
| 2026-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-31 | Body height | 183 | cm | S |
| 2026-08-31 | Body weight | 92.8 | kg | S |
| 2026-08-31 | Body mass index (BMI) [Ratio] | 27.7 | kg/m2 | S |
| 2026-08-31 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-08-31 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-31 | Heart rate | 72 | /min | S |
| 2026-08-31 | Respiratory rate | 14 | /min | S |
| 2026-08-31 | Body temperature | 36.6 | Cel | S |
| 2026-08-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-11 | Body height | 183 | cm | S |
| 2026-05-11 | Body weight | 95.4 | kg | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 28.5 | kg/m2 | S |
| 2026-05-11 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-05-11 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-05-11 | Heart rate | 90 | /min | S |
| 2026-05-11 | Respiratory rate | 16 | /min | S |
| 2026-05-11 | Body temperature | 37.5 | Cel | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-27 | Body height | 183 | cm | S |
| 2026-07-27 | Body weight | 93.6 | kg | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 2026-07-27 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-27 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-07-27 | Heart rate | 74 | /min | S |
| 2026-07-27 | Respiratory rate | 14 | /min | S |
| 2026-07-27 | Body temperature | 36.6 | Cel | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-02 | Establishing primary care: heavy drinking, low mood and forgetfulness a year after two plane crashes, with high blood pressure and abnormal liver and iron tests on the intake panel | finished | S |
| 2026-03-16 | Two-week review with the hepatology consultation: HFE result, liver stiffness and the phlebotomy plan | finished | S |
| 2026-04-13 | Six-week review: phlebotomy, drinking, mood, blood pressure and liver imaging | finished | S |
| 2026-06-08 | Fourteen-week review: phlebotomy, the decision to stop drinking, mood and blood pressure | finished | S |
| 2026-08-31 | Six-month review: iron, liver, mood, memory and the plan for maintenance phlebotomy | finished | S |
| 2026-05-11 | Same-day sick visit for a fishhook wound of the hand with early cellulitis | finished | S |
| 2026-07-27 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Alcohol: AUDIT and DSM-5-TR assessment, brief intervention in his own terms, naltrexone 50 mg daily, thiamine, a drinking diary, a goal he chooses and revisits, withdrawal precautions if he stops (no abrupt stop at his intake level without a plan), and mutual-help or counseling options offered | completed | GL-APA-AUD-2018, GL-ASAM-AWM-2020, GL-USPSTF-ALC-2018 | S |
| Hepatology consultation for raised iron studies and liver tests in a heavy drinker: to confirm the cause, stage the liver, and plan treatment | completed | GL-AASLD-HH-2011, GL-ACG-HH-2019 | S |
| Hemochromatosis: weekly phlebotomy of 500 mL with a hemoglobin check before each, to a ferritin of 50 to 100 ng/mL, then maintenance; MRI with liver iron quantification and elastography instead of biopsy; no iron or vitamin C supplements, no raw shellfish; no alcohol advised while iron is high and the liver is healing; HFE and iron testing offered to first-degree relatives through a letter he may share, with no result recorded here | completed | GL-AASLD-HH-2011, GL-ACG-HH-2019 | S |
| Depression: PHQ-9 at each visit, weekly psychotherapy (cognitive behavioral therapy) with the clinic's behavioral health clinician, sertraline, the Mood Disorder Questionnaire before the antidepressant, a structured safety assessment with a written safety plan, lethal-means counseling about firearms, the 988 Suicide & Crisis Lifeline, and safety review at every visit | completed | GL-VADOD-MDD-2022, GL-SUICIDE-2024, GL-CMID-2026 | S |
| Post-concussion symptoms: symptom-based care (headache plan without daily analgesics, sleep routine, graded activity, writing in shorter sessions), MoCA repeated after three months with less alcohol, no routine brain imaging without warning signs, and neuropsychological testing if thinking does not improve; chronic traumatic encephalopathy not diagnosed | completed | GL-VADOD-MTBI-2021 | S |
| Hypertension: home blood pressure monitoring, amlodipine, less alcohol and salt, ECG and urine albumin at diagnosis, echocardiogram for stage 2 hypertension, and a target below 130/80 mmHg | completed | GL-CMID-2026, GL-ACC-AHA-HTN-2017 | S |
| Prediabetes: HbA1c repeated at six months, less alcohol, activity and diet; iron overload and alcohol both raise the risk of diabetes | completed | GL-USPSTF-DM-2021, GL-ACG-HH-2019 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Drinking goal chosen by him: no more than two drinks a day and none before evening, then reconsidered once the liver results are known | 2026-06-08 | completed | Reduced to three or four drinks a day by six weeks; he then chose to stop, and has had no alcohol for three weeks | S |
| Ferritin 50 to 100 ng/mL with weekly phlebotomy, then maintenance | 2026-08-31 | active | Ferritin 1,460 to 268 ng/mL after twenty-two sessions; induction continuing | S |
| PHQ-9 below 5 | 2026-08-31 | active | PHQ-9 16 to 5 at six months; response, nearly in remission | S |
| Blood pressure below 130/80 mmHg | 2026-08-31 | completed | 126/78 in clinic and an average of 124/76 at home on amlodipine 10 mg | S |
| Fewer headaches and clearer thinking, so that he can write | 2026-08-31 | active | Headaches once a week from three; MoCA 25 to 27; writing every morning | S |
Structured synthetic safety assessment on 2026-03-02: current ideation present, intent absent, plan absent. Outpatient care with close follow-up. C-SSRS screen: wish to be dead on several days in the past month; no active thoughts of suicide, intent, plan, preparation or past attempt. Risk factors reviewed without detail: a father who died by suicide, other deaths by suicide in his family, heavy drinking, depression, repeated head injuries, chronic pain, and firearms at home. Lethal-means counseling about firearms was done respectfully, as a hunter's safety question rather than a judgment: he chose to have his guns held in the locked storage at his shooting club while his mood and drinking are treated, and to keep no ammunition at home. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit [S]